Thomas J Caperna

US Patent:

8486699, Jul 16, 2013

Filed:

May 23, 2008

Appl. No.:

12/154631

Inventors:

Neil C. Talbot - Clarksville MD, US
Thomas J. Caperna - Arnold MD, US
Ryan Willard - Halethorpe MD, US

Assignee:

The United States of America as Represented by the Secretary of Agriculture - Washington DC

International Classification:

C12N 5/02
C12N 5/00
C12N 5/06
C12N 5/08

US Classification:

435400, 435325, 435363, 435395, 435398, 435403, 435810

Abstract:

Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line. The unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. The growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i. e. , inducible CYP450 activity, ammonia clearance, and urea production of the PICM-19H cells were evaluated for their application in artificial liver devices. PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles and display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. The data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing.

US Patent:

20130344154, Dec 26, 2013

Filed:

Jun 4, 2013

Appl. No.:

13/909320

Inventors:

Thomas J Caperna - Arnold MD, US
Ryan R. Willard - Halethorpe MD, US

International Classification:

C12N 5/071
C12N 11/00

US Classification:

424490, 435325, 435177, 424 937

Abstract:

Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line. The unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. The growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production of the PICM-19H cells were evaluated for their application in artificial liver devices. PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles and display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. The data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing.

US Patent:

58664203, Feb 2, 1999

Filed:

Jul 1, 1996

Appl. No.:

8/674068

Inventors:

Neil C. Talbot - Silver Spring MD
Christopher W. Kemp - Frederick MD
Thomas J. Caperna - Arnold MD
Caird E. Rexroad - Gambrills MD
Vernon G. Pursel - Highland MD
Anne M. Powell - Bowie MD

Assignee:

The United States of America as represented by the Secretary of
Agriculture - Washington DC

International Classification:

C12N 500

US Classification:

435395

Abstract:

Continuous cultures of pluripotent parenchymal hepatocytes were derived from the epiblasts of pig blastocysts. The cultures are feeder-dependent and grow slowly with doubling times of 3 to 4 days. They differentiate into large secretory duct-like structures or form small canaliculi. In combination with feeder cells and, optionally, adult pig hepatocytes and macrophages, the cells are useful in an artificial liver device which may be utilized as temporary liver support for the mitigation of the pathological effects of liver failure.